GlassScriptPhysician profile
Nadia Zandy
NPI 1164137519
$5,972.89
in general payments reported to CMS, 2019-2025
22 companies · $3,102 in 2025
The $3,102 reported for 2025 was more than what 97% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $507 · 2024: $2,364 · 2025: $3,102.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,973.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,972.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $813.87 | 2023-2025 | Caplyta |
| Abbvie INC. | $764.79 | 2023-2025 | |
| Axsome Therapeutics, INC. | $623.82 | 2023-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $569.03 | 2023-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $486.61 | 2023-2025 | Ingrezza |
| Alkermes, INC. | $437.66 | 2023-2025 | Aristada, Lybalvi |
| Teva Pharmaceuticals USA, INC. | $338.54 | 2023-2025 | Austedo Xr, Austedo Xr |
| Ironshore Pharmaceuticals INC. | $307.63 | 2023-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $306.26 | 2025 | Jornay Pm |
| Bausch Health US, LLC | $234.03 | 2023-2025 | Aplenzin, Wellbutrin |
| Lundbeck LLC | $222.68 | 2023-2025 | Rexulti |
| Corium, LLC | $146.76 | 2023-2025 | Azstarys |
| Vanda Pharmaceuticals INC. | $126.53 | 2025 | Fanapt |
| Janssen Pharmaceuticals, INC | $118.72 | 2024-2025 | Invega Sustenna, Invega Trinza |
| Neos Therapeutics, LP | $89.27 | 2023-2024 | Adzenys Xr-Odt |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $86.25 | 2024-2025 | Loreev Xr |
| Supernus Pharmaceuticals, INC. | $85.66 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $82.69 | 2023-2024 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $64.52 | 2025 | Cobenfy |
| Harmony Biosciences LLC | $25.24 | 2024 | |
| Tris Pharma INC | $23.88 | 2023 | Dyanavel Xr |
| Owp Pharmaceuticals, INC. | $18.45 | 2025 | Subvenite |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadia Zandy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.